Quinfamide

Summary

Quinfamide (CHEMBL2107014) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 354.2 Da · C16H13Cl2NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107014
Name	Quinfamide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	71743
Molecular formula	C16H13Cl2NO4
Molecular weight	354.2
InChIKey	SBJGFIXQRZOVTO-UHFFFAOYSA-N

SMILES: C1CC2=C(C=CC(=C2)OC(=O)C3=CC=CO3)N(C1)C(=O)C(Cl)Cl

IUPAC name: [1-(2,2-dichloroacetyl)-3,4-dihydro-2H-quinolin-6-yl] furan-2-carboxylate

Also known as: Quinfamida, Quinfamide, WIN 40014, WIN-40014, QUINFAMIDE, quinfamide

Patent coverage: 121 distinct patent families (513 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 511 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Estrogen receptor, Muscarinic acetylcholine receptor M1, Adenosine receptor A1, Alpha-1A adrenergic receptor, Adenosine receptor A3.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02385058	PHASE4	COMPLETED	Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).